Barinthus Biotherapeutics (BRNS) Non-Current Assets (2020 - 2026)

Barinthus Biotherapeutics has reported Non-Current Assets for 7 years, with the latest figure at $19.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 39.34% year-over-year to $19.5 million; the trailing twelve-month figure through Mar 2026 stood at $91.4 million (down 47.94% YoY), and the FY2025 full-year result was $20.4 million, down 41.08% from the prior year.
• Non-Current Assets for Q1 2026 stood at $19.5 million, down from $20.4 million in the prior quarter.
• The five-year high for Non-Current Assets was $61.4 million in Q2 2023, with the low at $19.5 million in Q1 2026.
• Historically, Non-Current Assets has averaged $46.5 million across 5 years, with a median of $55.3 million in 2022.
• Annual changes were most pronounced in 2022 — Non-Current Assets soared 1789.55% — and 2025, when it slumped 58.51%.
• Barinthus Biotherapeutics' Non-Current Assets stood at $57.2 million in 2022, then increased by 0.76% to $57.6 million in 2023, then tumbled by 39.96% to $34.6 million in 2024, then plunged by 41.08% to $20.4 million in 2025, then slipped by 4.42% to $19.5 million in 2026.
• The last three Non-Current Assets figures came in at $19.5 million (Q1 2026), $20.4 million (Q4 2025), and $22.4 million (Q3 2025), per Business Quant data.